A Century After the Eugenics Movement, the U.S. Is Again Barring Disabled Immigrants
By Emma Cieslik,
Ms. Magazine
| 11. 20. 2025
A revived “public charge” standard directs officers to deny visas to people with disabilities, chronic illnesses and age-related conditions—echoing the exclusionary policies of the early 20th century.
Photo by The New York Public Library on Unsplash
This piece includes sanist slurs used in the late 19th and early 20th centuries.
This month, Secretary of State Marco Rubio instructed visa officers to consider obesity and other chronic health conditions, such as heart disease, cancer and diabetes, as justification to deny people visas to the United States. The guidance—along with direction that visa officers can reject visa applications for people beyond retirement age and if their dependents are elderly or disabled—is part of a “public charge” rulethat allows the government to deny visas and green cards if the person might use social welfare programs or be institutionalized.
Many were outraged and shocked, observing the Trump administration’s new expansion of the “public charge” rule—directing visa officers to deny entry to people with disabilities, chronic illnesses or age-related conditions—as a modern revival of eugenic immigration policy designed to exclude, control and institutionalize disabled and marginalized people. The “public charge” rule is not new, but this new definition seeks to restrict citizenship on the basis of possible institutionalization as the Trump...
Related Articles
By Vittoria Vardanega, SWI swissinfo.ch | 02.13.2026
In recent years, sperm donation has produced family trees of unprecedented size, stretching across countries and, in some cases, continents. Stories of “mass donors” have captured public attention, most recently through the Netflix documentary series, The Man with 1,000 Kids...
By Jonathan D. Moreno, Hastings Center Bioethics Forum | 02.09.2026
When I began to write a book about bioethics and the rules-based international order, the idea that the world was facing the greatest geopolitical change since World War II was uncontroversial for those who were paying attention to such esoterica...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...